Basic Information
| LncRNA/CircRNA Name | MIR31HG |
| Synonyms | MIR31HG, hsa-lnc-31, LncHIFCAR |
| Region | GRCh38_9:21455642-21559669 |
| Ensemble | ENSG00000171889 |
| Refseq | NR_027054 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Gefitinib | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot etc. |
| Sample | cell line (PC9) |
| Expression Pattern | up-regulated |
| Function Description | Expression of various lncRNAs differed significantly between the two cell lines, and MIR31HG expression in particular was significantly higher in PC9-R cells. Furthermore, overexpression of MIR31HG lncRNAs may contribute to gefitinib resistance in PC9-R cells through the EGFR/PI3K/AKT pathway, |
| Pubmed ID | 28529576 |
| Year | 2017 |
| Title | Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway |
External Links
| Links for MIR31HG | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |